Back to Journals » International Journal of Nanomedicine » Volume 2 » Issue 1

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

       

Authors Theresa Barnes, Robert Moots

Published 15 April 2007 Volume 2007:2(1) Pages 3—7

Download Article [PDF] 


Theresa Barnes, Robert Moots

Academic Rheumatology, University of Liverpool, UK

Abstract: Anti-TNFa therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other infl ammatory diseases. These drugs are powerful and expensive. A new anti-TNFa agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNFa with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.

Keywords: certolizumab pegol, TNFa, rheumatoid arthritis, nanomolecule

Download Article [PDF]